Alkermes plc (ALKS) Tops Q4 EPS by 3c; Announces Positive Top-Line Data from ARISTADA PK Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial Expectations for 2016
February 25, 2016 7:01 AM ESTRevenues of $628 Million, GAAP Loss Per Share of $1.52 and Non-GAAP Diluted Loss Per Share of $0.36 Reported for Calendar 2015
VIVITROL® Net Sales Grew by 53% Year-Over-Year to $144.4 Million
2016 Revenues Expected to Grow by 15% to 20%, Driven by Continuing
Growth of VIVITROL and Launch of ARISTADA® Into
Rapidly Growing Long-Acting
Antipsychotic Market
Pivotal Clinical Programs Underway for Late-Stage CNS Pipeline for Schizophrenia, Multiple Sclerosis and Major Depressive Disorder
DUBLIN--(BUSINESS WIRE)--... More
Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia
February 25, 2016 7:00 AM ESTCompany to File Supplemental New Drug Application With FDA in Second Half of 2016
Potential New Offering Would Expand Range of ARISTADA Doses to Three Interval Options: Once Monthly, Once Every Six Weeks and Once Every Two Months
DUBLIN, Ireland--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) today announced positive topline data from a randomized, open-label, pharmacokinetic (PK) study evaluating a two-month... More
